Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

Trial Profile

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 14 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top